This recombinant monoclonal antibody is developed as a research-grade biosimilar to Mertuzumab, targeting BSG (basigin), also known as CD147 or EMMPRIN (extracellular matrix metalloproteinase inducer). BSG is a transmembrane glycoprotein belonging to the immunoglobulin superfamily that plays critical roles in multiple cellular processes including stimulation of matrix metalloproteinase production, regulation of monocarboxylate transporters, and facilitation of cell-cell interactions. The protein is highly expressed in various malignancies and has been implicated in tumor progression, metastasis, angiogenesis, and drug resistance. BSG also serves as a receptor for certain pathogens and is involved in inflammatory responses, making it a significant target in cancer biology and infectious disease research.
Mertuzumab, the reference antibody for this biosimilar, was developed to target BSG-expressing tumors and has been investigated in oncology research settings. This biosimilar antibody provides researchers with a valuable tool for investigating BSG-mediated signaling pathways, exploring therapeutic targeting strategies, and studying the protein's role in tumor microenvironment interactions and metabolic regulation across various disease models.
Email: support@cusabio.com
Distributors Worldwide